Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 chemotherapy regimens for pancreatic adenocarcinoma
2011-002026-52Phase 3Active
- Sponsor
- Unicancer
- Start
- Jun 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of gemcitabine, fluorouracil, irinotecan, oxaliplatin, folinic acid and 1 more in pancreatic adenocarcinoma (PDAC), sponsored by Unicancer. Started Jun 2011; status: active.
02
Drugs
gemcitabinefluorouracilirinotecanoxaliplatinfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-002026-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002026-52.